AR020093A1 - Una cepa aislada de virus de hepatitis, acido nucleico aislado que codifica un polipeptido de la cepa, vector que comprende dicho acido nucleico, sistemavector huesped para la produccion del polipeptido, el polipeptido, metodo para su produccion, oligonucleotido para hibridarse con el acido nucleico - Google Patents
Una cepa aislada de virus de hepatitis, acido nucleico aislado que codifica un polipeptido de la cepa, vector que comprende dicho acido nucleico, sistemavector huesped para la produccion del polipeptido, el polipeptido, metodo para su produccion, oligonucleotido para hibridarse con el acido nucleicoInfo
- Publication number
- AR020093A1 AR020093A1 ARP990102962A ARP990102962A AR020093A1 AR 020093 A1 AR020093 A1 AR 020093A1 AR P990102962 A ARP990102962 A AR P990102962A AR P990102962 A ARP990102962 A AR P990102962A AR 020093 A1 AR020093 A1 AR 020093A1
- Authority
- AR
- Argentina
- Prior art keywords
- polypeptide
- virus
- strain
- nucleic acid
- isolated
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 12
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 11
- 229920001184 polypeptide Polymers 0.000 title abstract 9
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 9
- 241000700605 Viruses Species 0.000 title abstract 8
- 108020004707 nucleic acids Proteins 0.000 title abstract 7
- 102000039446 nucleic acids Human genes 0.000 title abstract 7
- 150000007523 nucleic acids Chemical class 0.000 title abstract 7
- 208000006454 hepatitis Diseases 0.000 title abstract 3
- 231100000283 hepatitis Toxicity 0.000 title abstract 3
- UDPGUMQDCGORJQ-UHFFFAOYSA-N (2-chloroethyl)phosphonic acid Chemical compound OP(O)(=O)CCCl UDPGUMQDCGORJQ-UHFFFAOYSA-N 0.000 title 1
- 238000004690 coupled electron pair approximation Methods 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 abstract 3
- 238000004519 manufacturing process Methods 0.000 abstract 3
- 241000700721 Hepatitis B virus Species 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 238000002955 isolation Methods 0.000 abstract 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000000470 constituent Substances 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 208000002672 hepatitis B Diseases 0.000 abstract 1
- 229960002520 hepatitis vaccine Drugs 0.000 abstract 1
- 229930182817 methionine Natural products 0.000 abstract 1
- 238000012163 sequencing technique Methods 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Una cepa aislada del virus de hepatitis, un ácido nucleico aislado que codifica un polipéptido de la cepa aislada de virus, un vector que comprende dichoácido nucleico, un sistema vector huésped para la produccion de polipéptido de la cepa aislada devirus, un método para producir dicho polipéptido, un métodopara producir un péptido, un polipéptido de dicha cepa aislada de virus, un oligonucleotido para hibridarse dentro del ácido nucleico, método para obtneranticuerpos paa el polipéptido, un anticuerpo obtenido por el método, un método paa determinar la infeccion en un sujeto, un método para identificar uncompuesto químico, una composicion que comprende un péptido, un método para tratar un sujeto infectado, un método para evitar una infeccion, un método pararastrear fluidos en el sujeto, una vacuna contra hepatitis que comprende la cepa del virus de hepatitis. Esta invencion provee una cepa aislada de virus dehepatitis B designada antígeno de superficie de virus de hepatitis B humana-cepaS133 Oon (metionina a trionina) cuyo genoma viral constituyente estádepositado bajo los numeros de acceso P97121501, P97121502 y P97212503 en la Coleccion Europea de Cultivos de Células el 15 de diciembre de 1997. Estainvencion provee también unácido nucleico aislado que codifica un polipéptido que es un antígeno mayor mutante de superficie de una cepa de virus de hepatitisB. La aislacion del virus mutante permite el secuenciado de los ácidos nucleicos y los polipéptidos de los virus los cuales a cambio permiten la produccion devarios métodos los cuales no son posibles previo a la aislacion del virus. Estos métodos incluyen, pero no son limitantes a los métodos de deteccion deinfeccion, métodos de tratamiento.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/SG1998/000046 WO1999066048A1 (en) | 1998-06-19 | 1998-06-19 | A mutant human hepatitis b viral strain and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR020093A1 true AR020093A1 (es) | 2002-04-10 |
Family
ID=20429862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990102962A AR020093A1 (es) | 1998-06-19 | 1999-06-18 | Una cepa aislada de virus de hepatitis, acido nucleico aislado que codifica un polipeptido de la cepa, vector que comprende dicho acido nucleico, sistemavector huesped para la produccion del polipeptido, el polipeptido, metodo para su produccion, oligonucleotido para hibridarse con el acido nucleico |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US6558675B1 (es) |
| EP (1) | EP1098981A1 (es) |
| JP (1) | JP2002518014A (es) |
| KR (1) | KR100498118B1 (es) |
| CN (1) | CN1322251A (es) |
| AR (1) | AR020093A1 (es) |
| AU (1) | AU756866B2 (es) |
| BG (1) | BG105066A (es) |
| BR (1) | BR9815913A (es) |
| CA (1) | CA2330935C (es) |
| HU (1) | HUP0103409A3 (es) |
| IL (1) | IL140364A0 (es) |
| IS (1) | IS5778A (es) |
| MX (1) | MXPA00012720A (es) |
| MY (1) | MY118955A (es) |
| NO (1) | NO20006456L (es) |
| NZ (1) | NZ508890A (es) |
| PL (1) | PL192129B1 (es) |
| TR (1) | TR200003777T2 (es) |
| UA (1) | UA73476C2 (es) |
| WO (1) | WO1999066048A1 (es) |
| YU (1) | YU80600A (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006132598A1 (en) * | 2005-06-07 | 2006-12-14 | Temasek Life Sciences Laboratory Limited | Porcine circovirus type 2 vaccines |
| EP3708176A1 (en) * | 2019-03-15 | 2020-09-16 | Centre National De La Recherche Scientifique -Cnrs- | Mutant vsv ectodomain polypeptide and uses thereof |
| CN119770638A (zh) | 2019-09-30 | 2025-04-08 | 吉利德科学公司 | Hbv疫苗和治疗hbv的方法 |
| CN113201051B (zh) * | 2021-04-27 | 2022-08-02 | 复旦大学 | 一种乙肝病毒表面蛋白突变体及其在抗乙肝病毒中的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9401987D0 (en) | 1994-02-02 | 1994-03-30 | Imperial College | Modified nucleic acid |
| US5980901A (en) | 1996-09-18 | 1999-11-09 | The Board Of Regents Of The University Of Texas System | Viral defective interfering particles and uses thereof |
-
1998
- 1998-06-19 EP EP98926023A patent/EP1098981A1/en not_active Withdrawn
- 1998-06-19 HU HU0103409A patent/HUP0103409A3/hu unknown
- 1998-06-19 YU YU80600A patent/YU80600A/sh unknown
- 1998-06-19 CN CN98814201A patent/CN1322251A/zh active Pending
- 1998-06-19 UA UA2000127297A patent/UA73476C2/uk unknown
- 1998-06-19 BR BR9815913-5A patent/BR9815913A/pt not_active Application Discontinuation
- 1998-06-19 PL PL345573A patent/PL192129B1/pl not_active IP Right Cessation
- 1998-06-19 CA CA002330935A patent/CA2330935C/en not_active Expired - Fee Related
- 1998-06-19 NZ NZ508890A patent/NZ508890A/en unknown
- 1998-06-19 KR KR10-2000-7014456A patent/KR100498118B1/ko not_active Expired - Fee Related
- 1998-06-19 IL IL14036498A patent/IL140364A0/xx unknown
- 1998-06-19 WO PCT/SG1998/000046 patent/WO1999066048A1/en not_active Ceased
- 1998-06-19 AU AU77951/98A patent/AU756866B2/en not_active Ceased
- 1998-06-19 MX MXPA00012720A patent/MXPA00012720A/es not_active Application Discontinuation
- 1998-06-19 TR TR2000/03777T patent/TR200003777T2/xx unknown
- 1998-06-19 JP JP2000554857A patent/JP2002518014A/ja active Pending
- 1998-06-19 US US09/719,528 patent/US6558675B1/en not_active Expired - Fee Related
-
1999
- 1999-06-18 AR ARP990102962A patent/AR020093A1/es unknown
- 1999-06-18 MY MYPI99002517A patent/MY118955A/en unknown
-
2000
- 2000-12-18 NO NO20006456A patent/NO20006456L/no not_active Application Discontinuation
- 2000-12-18 BG BG105066A patent/BG105066A/xx unknown
- 2000-12-19 IS IS5778A patent/IS5778A/is unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU756866B2 (en) | 2003-01-23 |
| UA73476C2 (en) | 2005-08-15 |
| YU80600A (sh) | 2005-06-10 |
| US6558675B1 (en) | 2003-05-06 |
| PL345573A1 (en) | 2001-12-17 |
| HUP0103409A2 (hu) | 2001-12-28 |
| AU7795198A (en) | 2000-01-05 |
| KR100498118B1 (ko) | 2005-07-01 |
| CA2330935A1 (en) | 1999-12-23 |
| IL140364A0 (en) | 2002-02-10 |
| HUP0103409A3 (en) | 2003-10-28 |
| NO20006456L (no) | 2001-02-16 |
| JP2002518014A (ja) | 2002-06-25 |
| BR9815913A (pt) | 2001-12-26 |
| NO20006456D0 (no) | 2000-12-18 |
| EP1098981A1 (en) | 2001-05-16 |
| BG105066A (en) | 2001-09-28 |
| WO1999066048A1 (en) | 1999-12-23 |
| IS5778A (is) | 2000-12-19 |
| MY118955A (en) | 2005-02-28 |
| PL192129B1 (pl) | 2006-09-29 |
| MXPA00012720A (es) | 2002-05-08 |
| CA2330935C (en) | 2005-05-10 |
| CN1322251A (zh) | 2001-11-14 |
| KR20010106129A (ko) | 2001-11-29 |
| TR200003777T2 (tr) | 2001-06-21 |
| NZ508890A (en) | 2004-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111088283B (zh) | mVSV病毒载体及其病毒载体疫苗、一种基于mVSV介导的新冠肺炎疫苗 | |
| CN113416259B (zh) | 一种β冠状病毒抗原、其制备方法和应用 | |
| Hanke et al. | Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice | |
| JPH06509710A (ja) | バキュロウイルスにおけるインフルエンザａのｍ２蛋白の改良発現及びｍ２蛋白の使用 | |
| Delbac et al. | On proteins of the microsporidian invasive apparatus: complete sequence of a polar tube protein of Encephalitozoon cuniculi | |
| KR20180002872A (ko) | 신규한 배큘로바이러스 벡터 및 사용 방법 | |
| AR020092A1 (es) | Una cepa aislada de virus de hepatitis, acido nucleico aislado que codifica un polipeptido de la cepa, vector que comprende dicho acido nucleico, sistemavector huesped para la produccion del polipeptido, el polipeptido, metodo para su produccion, metodo para obtener anticuerpos contra el polipeptido | |
| CA2427578A1 (en) | A recombinant newcastle disease virus nucleoprotein mutant as a marker vaccine | |
| Emini et al. | Antigenic analysis of the Epstein-Barr virus major membrane antigen (gp350/220) expressed in yeast and mammalian cells: implications for the development of a subunit vaccine | |
| WO2006009011A1 (ja) | コロナウイルススパイクｓ１融合蛋白及びその発現ベクター | |
| RU2181379C2 (ru) | Пептид (варианты) и способ его производства, фармацевтическое средство, антитело и способ его производства | |
| KR20180038557A (ko) | 타겟 폴리펩티드를 제시하기 위한 폴리펩티드 캐리어 및 이의 용도 | |
| HUP9901005A2 (hu) | Herpeszvírusok RFHV/KSHV-alcsaládjába tartozó vírusokból származó glikoprotein-B | |
| AR020093A1 (es) | Una cepa aislada de virus de hepatitis, acido nucleico aislado que codifica un polipeptido de la cepa, vector que comprende dicho acido nucleico, sistemavector huesped para la produccion del polipeptido, el polipeptido, metodo para su produccion, oligonucleotido para hibridarse con el acido nucleico | |
| CN101706497A (zh) | 人tff3的elisa检测试剂盒 | |
| US6777247B2 (en) | Nervous necrosis virus protein | |
| Xu et al. | Assessment of antigenicity and genetic variation of glycoprotein B of murine cytomegalovirus | |
| WO2000004921A1 (en) | Avian leukosis virus subgroup j envelope gene product for diagnosis and vaccine | |
| Rodríguez et al. | A human immunodeficiency virus type 1 Env-granulocyte-macrophage colony-stimulating factor fusion protein enhances the cellular immune response to Env in a vaccinia virus-based vaccine. | |
| KR100785397B1 (ko) | 인체 파필로마 바이러스 유사 입자를 생산하는 재조합아데노바이러스 벡터 및 자궁경부암 생백신 | |
| CN100479858C (zh) | 一种重组痘苗-sars疫苗及其制备方法 | |
| AU643506B2 (en) | Polypeptides and DNA encoding same, associated with human malaria parasites | |
| RU2856219C1 (ru) | Рекомбинантная плазмидная ДНК pET-22b-sars"XBB.1.5", обеспечивающая получение рекомбинантного белка коронавируса S-SARS"XBB.1.5", обладающего способностью определять уровень вирус-специфических IgG к антигенному варианту вируса "кракен" - SARS"XBB.1.5" | |
| CN115894713B (zh) | 异源三聚体化融合蛋白、组合物及其应用 | |
| KR101648106B1 (ko) | A형 간염 바이러스 항원 및 e형 간염 바이러스 항원 동시 생산방법 및 생산된 항원을 함유하는 간염 예방 백신 및 진단 키트 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |